WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007095749) CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF TROP-2
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/095749    International Application No.:    PCT/CA2007/000283
Publication Date: 30.08.2007 International Filing Date: 23.02.2007
IPC:
C12N 5/16 (2006.01), A61K 39/00 (2006.01), A61K 39/395 (2006.01), A61K 47/48 (2006.01), A61K 51/10 (2006.01), A61P 35/00 (2006.01), C07K 16/18 (2006.01), C07K 16/30 (2006.01), C12P 21/08 (2006.01), G01N 33/574 (2006.01), G01N 33/577 (2006.01)
Applicants: ARIUS RESEARCH INC. [CA/CA]; 55 York Street, 15th Floor, Toronto, Ontario M5J 1R7 (CA)
Inventors: YOUNG, David, S. F.; (CA).
FINDLAY, Helen, P.; (CA).
HAHN, Susan, E.; (CA).
DaCRUZ, Luis, A. G.; (CA).
FERRY, Alison, L.; (CA)
Agent: SINGLEHURST, John, C.; Finlayson & Singlehurst, 70 Gloucester Street, Ottawa, Ontario K2P 0A2 (CA)
Priority Data:
60/776,466 24.02.2006 US
Title (EN) CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF TROP-2
(FR) MÉDIATION DE CYTOTOXICITÉ DE CELLULES METTANT EN ÉVIDENCE L'EXPRESSION SUPERFICIELLE DE TROP-2
Abstract: front page image
(EN)The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
(FR)L'invention concerne un procédé de production d'anticorps modifiant les maladies cancéreuses, dans lequel un nouveau paradigme de criblage est utilisé. Par la ségrégation des anticorps anticancéreux en faisant appel à la cytotoxicité des cellules cancéreuses comme résultat final, le procédé permet la production d'anticorps anticancéreux à des fins thérapeutiques et diagnostiques. Ces anticorps peuvent être utilisés dans la stadification et le diagnostic d'un cancer, ainsi que pour traiter des tumeurs primaires et des métastases tumorales. Lesdits anticorps anticancéreux peuvent être conjugués à des toxines, des enzymes, des composés radioactifs, des cytokines, des interférons, des fragments cibles ou rapporteurs et des cellules hématogènes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)